Business Context and Reporting Period
Company: Estrella Immunopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 3, 2025
Reporting Period: Event-based report regarding a specific corporate development on November 3, 2025.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is a clinical development milestone:
- Event: Successful completion of the second dose cohort in the Phase I portion of the STARLIGHT-1 Phase I/II clinical trial.
- Asset: EB103.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the clinical milestone. The filing states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability.
Guidance and Risks: The filing text does not provide specific forward-looking guidance, updated financial outlook, or a detailed discussion of risks and contingencies beyond the standard legal disclaimers regarding the press release.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific safety and tolerability data regarding the second dose cohort.
- Confirm the timeline for the next phase or dose cohort of the STARLIGHT-1 trial.
- Review recent 10-Q or 10-K filings for the Company's current cash runway and liquidity position, as this 8-K does not contain financial data.
- Monitor for any subsequent filings regarding the transition from Phase I to Phase II of the EB103 trial.